Developing PRISM: A Pragmatic Institutional Survey and Bench Marking Tool to Measure Digital Research Maturity of Cancer Centers.


Journal

Applied clinical informatics
ISSN: 1869-0327
Titre abrégé: Appl Clin Inform
Pays: Germany
ID NLM: 101537732

Informations de publication

Date de publication:
Aug 2024
Historique:
medline: 12 9 2024
pubmed: 12 9 2024
entrez: 11 9 2024
Statut: ppublish

Résumé

 Multicenter precision oncology real-world evidence requires a substantial long-term investment by hospitals to prepare their data and align on common Clinical Research processes and medical definitions. Our team has developed a self-assessment framework to support hospitals and hospital networks to measure their digital maturity and better plan and coordinate those investments. From that framework, we developed PRISM for Cancer Outcomes: PR: agmatic I: nstitutional S: urvey and benchM: arking.  The primary objective was to develop PRISM as a tool for self-assessment of digital maturity in oncology hospitals and research networks; a secondary objective was to create an initial benchmarking cohort of >25 hospitals using the tool as input for future development.  PRISM is a 25-question semiquantitative self-assessment survey developed iteratively from expert knowledge in oncology real-world study delivery. It covers four digital maturity dimensions: (1) Precision oncology, (2) Clinical digital data, (3) Routine outcomes, and (4) Information governance and delivery. These reflect the four main data types and critical enablers for precision oncology research from routine electronic health records.  During piloting with 26 hospitals from 19 European countries, PRISM was found to be easy to use and its semiquantitative questions to be understood in a wide diversity of hospitals. Results within the initial benchmarking cohort aligned well with internal perspectives. We found statistically significant differences in digital maturity, with Precision oncology being the most mature dimension, and Information governance and delivery the least mature.  PRISM is a light footprint benchmarking tool to support the planning of large-scale real-world research networks. It can be used to (i) help an individual hospital identify areas most in need of investment and improvement, (ii) help a network of hospitals identify sources of best practice and expertise, and (iii) help research networks plan research. With further testing, policymakers could use PRISM to better plan digital investments around the Cancer Mission and European Digital Health Space.

Sections du résumé

BACKGROUND BACKGROUND
 Multicenter precision oncology real-world evidence requires a substantial long-term investment by hospitals to prepare their data and align on common Clinical Research processes and medical definitions. Our team has developed a self-assessment framework to support hospitals and hospital networks to measure their digital maturity and better plan and coordinate those investments. From that framework, we developed PRISM for Cancer Outcomes: PR: agmatic I: nstitutional S: urvey and benchM: arking.
OBJECTIVES OBJECTIVE
 The primary objective was to develop PRISM as a tool for self-assessment of digital maturity in oncology hospitals and research networks; a secondary objective was to create an initial benchmarking cohort of >25 hospitals using the tool as input for future development.
METHODS METHODS
 PRISM is a 25-question semiquantitative self-assessment survey developed iteratively from expert knowledge in oncology real-world study delivery. It covers four digital maturity dimensions: (1) Precision oncology, (2) Clinical digital data, (3) Routine outcomes, and (4) Information governance and delivery. These reflect the four main data types and critical enablers for precision oncology research from routine electronic health records.
RESULTS RESULTS
 During piloting with 26 hospitals from 19 European countries, PRISM was found to be easy to use and its semiquantitative questions to be understood in a wide diversity of hospitals. Results within the initial benchmarking cohort aligned well with internal perspectives. We found statistically significant differences in digital maturity, with Precision oncology being the most mature dimension, and Information governance and delivery the least mature.
CONCLUSION CONCLUSIONS
 PRISM is a light footprint benchmarking tool to support the planning of large-scale real-world research networks. It can be used to (i) help an individual hospital identify areas most in need of investment and improvement, (ii) help a network of hospitals identify sources of best practice and expertise, and (iii) help research networks plan research. With further testing, policymakers could use PRISM to better plan digital investments around the Cancer Mission and European Digital Health Space.

Identifiants

pubmed: 39260412
doi: 10.1055/s-0044-1788331
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

743-750

Informations de copyright

Thieme. All rights reserved.

Déclaration de conflit d'intérêts

None declared.

Auteurs

Carlos Berenguer Albiñana (CB)

IQVIA, London, United Kingdom.

Matteo Pallocca (M)

IRCCS Istituto Nazionale Tumori Regina Elena, Rome, Italy.

Hayley Fenton (H)

IQVIA, London, United Kingdom.
Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom.

Will Sopwith (W)

IQVIA, London, United Kingdom.
Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom.

Charlie Van Eden (CV)

IQVIA, London, United Kingdom.

Olof Akre (O)

Karolinska Comprehensive Cancer Center, Stockholm, Sweden.

Annika Auranen (A)

Tays Cancer Centre, Pirkanmaa, Finland.

François Bocquet (F)

Data Factory & Analytics Department, Institut de Cancérologie de l'Ouest, Nantes-Angers, France.

Marina Borges (M)

IQVIA, London, United Kingdom.
Instituto Português de Oncologia do Porto Francisco Gentil, Porto, Portugal.

Emiliano Calvo (E)

START Madrid-CIOCC, Centro Integral Oncológico Clara Campal, Madrid, Spain.

John Corkett (J)

Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom.

Serena Di Cosimo (SD)

Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

Nicola Gentili (N)

IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori," Meldola, Italy.

Julien Guérin (J)

Data Office, Institut Curie, Paris, France.

Sissel Jor (S)

Oslo University Hospital Cancer Center, Oslo, Norway.

Tomas Kazda (T)

Masaryk Memorial Cancer Institute, Brno, Jihomoravský, Czechia.

Alenka Kolar (A)

Institute of Oncology Ljubljana, Ljubljana, Slovenia.

Tim Kuschel (T)

Charité, Universitätsmedizin Berlin, Berlin, Germany.

Maria Julia Lostes (MJ)

Vall d'Hebron University Hospital, Barcelona, Spain.

Chiara Paratore (C)

University Hospital San Luigi Gonzaga of Orbassano, Orbassano TO, Italy.

Paolo Pedrazzoli (P)

Fondazione I.R.C.C.S. Policlinico San Matteo, Pavia PV, Italy.

Marko Petrovic (M)

Sestre Milosrdnice University Hospital, Zagreb, Croatia.

Jarno Raid (J)

Tartu University Hospital, Tartu, Tartumaa, Estonia.

Miriam Roche (M)

Trinity St James's Cancer Institute, Dublin, Ireland.

Christoph Schatz (C)

Biobank Innsbruck, Innsbruck, Austria.

Joelle Thonnard (J)

Cliniques Universitaires Saint-Luc, Brussels, Belgium.

Giovanni Tonon (G)

IRCCS San Raffaele Scientific Institute, Milan, Italy.

Alberto Traverso (A)

IRCCS San Raffaele Scientific Institute, Milan, Italy.
Maastricht Comprehensive Cancer Center, Maastricht, The Netherlands.
DIGICORE, Bruxelles, Belgium.

Andrea Wolf (A)

University Cancer Center Frankfurt (UCT), University Hospital, Goethe University, Frankfurt, Germany.

Ahmed H Zedan (AH)

Vejle Hospital, University of Southern Denmark, Vejle, Denmark.

Piers Mahon (P)

IQVIA, London, United Kingdom.
DIGICORE, Bruxelles, Belgium.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH